CVX Vs XOM Stock, Which Energy Play Is Best?
Chevron (NYSE:CVX) and Exxon Mobil (NYSE:XOM) are two of the…
Buy
60
FSPKF Quote, Financials, Valuation and Earnings
Last price:
$18.36
Seasonality move
:
4.85%
Day range:
$18.36 - $18.36
52-week range:
$16.14 - $25.71
Dividend yield:
1.37%
P/E ratio:
62.70x
P/S ratio:
10.06x
P/B ratio:
8.79x
Volume:
--
Avg. volume:
347
1-year change:
13.75%
Market cap:
$10.8B
Revenue:
$1.1B
EPS (TTM):
$0.18
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target DownsideNo price target exists because of limited analyst coverage.
-
Price Target UpsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Fisher & Paykel Healthcare has -- downside to fair value with a price target of -- per share.
FSPKF vs. S&P 500
-
Over the past 5 trading days, Fisher & Paykel Healthcare has overperformed the S&P 500 by 0.98% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Fisher & Paykel Healthcare does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Fisher & Paykel Healthcare has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Fisher & Paykel Healthcare reported revenues of --.
Earnings Growth
-
Fisher & Paykel Healthcare has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Fisher & Paykel Healthcare reported earnings per share of --.
Enterprise value:
10.8B
EV / Invested capital:
--
Price / LTM sales:
10.06x
EV / EBIT:
49.16x
EV / Revenue:
10.08x
PEG ratio (5yr expected):
--
EV / Free cash flow:
--
Price / Operating cash flow:
--
Enterprise value / EBITDA:
36.75x
Gross Profit (TTM):
$699.3M
Return On Assets:
7.55%
Net Income Margin (TTM):
9.45%
Return On Equity:
9.85%
Return On Invested Capital:
8.89%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-05-08 | 2024-05-08 | 2024-05-08 | |||
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -- | -- | -- | -- | -- | |
| EBITDA | -- | -- | -- | -- | -- | |
| Diluted EPS | -- | -- | -- | -- | -- | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $424.4M | $596.2M | $415.5M | $436.9M | $487.3M | |
| Total Assets | $1.1B | $1.4B | $1.2B | $1.4B | $1.5B | |
| Current Liabilities | $221.8M | $215.9M | $211.6M | $171.9M | $236.6M | |
| Total Liabilities | $269.6M | $312.3M | $353.7M | $382.3M | $320.9M | |
| Total Equity | $807.1M | $1.1B | $848.7M | $1B | $1.2B | |
| Total Debt | $72.5M | $78.7M | $64.5M | $193.8M | $95.8M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2015-04-30 | 2016-04-30 | 2017-04-30 | 2016-04-30 | 2017-04-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -- | -- | -- | $120.9M | $135.7M | |
| Cash From Investing | -- | -- | -- | $108.7M | $110.3M | |
| Cash From Financing | -- | -- | -- | -- | -- | |
| Free Cash Flow | -- | -- | -- | -- | -- | |
FSPKF
Sector
Market Cap
$10.8B
$34.5M
Price % of 52-Week High
71.41%
43.57%
Dividend Yield
1.37%
0%
Shareholder Yield
0.88%
-0.79%
1-Year Price Total Return
13.76%
-42.08%
Beta (5-Year)
1.233
0.660
Dividend yield:
1.37%
Annualized payout:
$0.25
Payout ratio:
84.82%
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$18.36
200-day SMA
Sell
Level
$20.19
Bollinger Bands (100)
Sell
Level
17.24 - 20.56
Chaikin Money Flow
Buy
Level
172.3K
20-day SMA
Buy
Level
$17.15
Relative Strength Index (RSI14)
Buy
Level
75.07
ADX Line
Buy
Level
48.4
Williams %R
Sell
Level
0
50-day SMA
Buy
Level
$17.52
MACD (12, 26)
Buy
Level
0.31
25-day Aroon Oscillator
Buy
Level
56
On Balance Volume
Neutral
Level
149.1K
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (19.1798)
Buy
CA Score
(Annual)
Level (1.6506)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (8)
Buy
Ohlson Score
Level (-1.7452)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Fisher & Paykel Healthcare is one of the three largest respiratory care device companies globally. It is the market leader in hospital use humidifiers, masks and related consumables and the number three player in the at-home treatment of sleep apnoea using respiratory devices. Both the hospital and homecare markets for respiratory devices are growing strongly in the developed markets in which Fisher & Paykel has a presence. The company earns 42% of its revenue in the U.S., 32% in Europe, 18% in Asia-Pacific and the remaining 8% in emerging markets. Fisher conducts its own R&D and has thousands of patents and pending applications. It manufactures in New Zealand and Mexico and has a multichannel distribution model.
Stock Forecast FAQ
In the current month, FSPKF has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The FSPKF average analyst price target in the past 3 months is --.
-
Where Will Fisher & Paykel Healthcare Stock Be In 1 Year?
According to analysts, the consensus estimate is that Fisher & Paykel Healthcare share price will drop to -- per share over the next 12 months.
-
What Do Analysts Say About Fisher & Paykel Healthcare?
Analysts are divided on their view about Fisher & Paykel Healthcare share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Fisher & Paykel Healthcare is a Sell and believe this share price will rise from its current level to --.
-
What Is Fisher & Paykel Healthcare's Price Target?
The price target for Fisher & Paykel Healthcare over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is FSPKF A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Fisher & Paykel Healthcare is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of FSPKF?
You can purchase shares of Fisher & Paykel Healthcare via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Fisher & Paykel Healthcare shares.
-
What Is The Fisher & Paykel Healthcare Share Price Today?
Fisher & Paykel Healthcare was last trading at $18.36 per share. This represents the most recent stock quote for Fisher & Paykel Healthcare. Yesterday, Fisher & Paykel Healthcare closed at $18.36 per share.
-
How To Buy Fisher & Paykel Healthcare Stock Online?
In order to purchase Fisher & Paykel Healthcare stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is it Safe to Invest in Google With OpenAI Threats?
For the last 20 years, Google parent company Alphabet (NASDAQ:GOOG,…
Is Broadcom Stock a Millionaire Maker?
Broadcom (Nasdaq: AVGO) stock has gone up more than 64%…
Stock Ideas
Buy
70
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 32x
Buy
61
Is NVDA Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 40x
Alerts
Buy
60
RGC alert for May 8
Regencell Bioscience Holdings [RGC] is up 22.96% over the past day.
Buy
52
SRPT alert for May 8
Sarepta Therapeutics [SRPT] is down 1.99% over the past day.
Buy
74
LIVN alert for May 8
LivaNova PLC [LIVN] is up 1.15% over the past day.
